tiprankstipranks
Barclays views GSK acquisition interest as positive for oncology stocks
The Fly

Barclays views GSK acquisition interest as positive for oncology stocks

Barclays analyst Peter Lawson views the Financial Times’ report that GSK (GSK) has interest in acquiring companies with a market capitalization in the $1.0B-$2.5B range, are under-the-radar, and with drugs that can be approved in the medium term as positive for the biotech tape. Renewed acquisition activity would help improve biotech sentiment and the overall index performance, Lawson tells investors in a research note. He sees a positive read-through to oncology companies with late-stage assets, namely Arvinas (ARVN), Replimune Group (REPL), Kura Oncology (KURA), Iovance Biotherapeutics (IOVA), Syndax (SNDX), SpringsWorks Therapeutics (SWTX), Bicycle Therapeutics (BCYC) and Karyopharm (KPTI).

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on ARVN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles